At the Eradicate Cancer Foundation (ECF), we are scouring the landscape and seascape to find companies that meet our mission — particularly those advancing the development of practical diagnostic tools for early detection of lung cancer. This effort is being undertaken in earnest to ensure that our very first grant contributions are made wisely.

In this regard, we were introduced to several firms through the CDL-BME program (the Biomedical Engineering stream) at the University of British Columbia. From that group, and for the time being, we have narrowed our focus and are currently taking a closer look at a company called Copoly.ai.

Copoly is a Canadian biotechnology start-up focused on advancing early cancer detection through artificial intelligence and molecular diagnostics. Its flagship product, OncoSage, is a non-invasive, blood-based test designed to detect early-stage (Stage I and II) lung cancer. The test leverages proprietary multi-omics analysis and AI-driven algorithms to identify cancer-associated molecular signals in blood samples. Importantly, it is designed to integrate with existing laboratory sequencing infrastructure, minimizing the need for new capital equipment.

At present, early validation data from a limited patient cohort indicate performance of 97% sensitivity and 93% specificity for Stage I/II lung cancer. While these preliminary results are encouraging, larger-scale validation studies are required to strengthen the clinical evidence base. Copoly is pursuing an Investigational Testing Authorization (ITA) pathway in Canada, targeted by year’s end, which would allow controlled clinical deployment under an Investigational Use Only framework. In parallel, the company is planning for CLIA/LDT alignment in the United States as part of a phased regulatory strategy.

Copoly is transitioning into its seed funding stage to support expanded validation studies, regulatory preparation, quality system development, and initial market entry in Ontario. Advancement to commercialization will require additional capital and strategic support. Given the platform’s potential to complement or enhance current lung cancer screening approaches, ECF is evaluating mechanisms to accelerate progress — including targeted grant sponsorship of validation studies, structured seed financing, and/or strategic investment participation. Additional support could include introductions to international clinical or commercial partners, beginning with Mexico and subsequently other Latin American markets.

From what we can gather about Copoly so far, there is hope, confidence, and significant promise for the early detection of lung cancer.

EW in Vancouver, Canada / March 2026